The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Halozyme Therapeutics HALO is scheduled to report fourth-quarter and full-year 2024 results on Feb. 18, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues ...

Helen Torley; President, Chief Executive Officer, Director; Halozyme Therapeutics Inc Nicole Labrosse; Chief Financial Officer, Senior Vice President; Halozyme Therapeutics Inc Good afternoon.

Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.